Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3492104 | 0.98 | ALDH1A1 (0.60) | ALDH1A1RAB9ANPC1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5009760 | 0.98 | ALDH1A1 (0.60) | ALDH1A1RAB9ANPC1HPGDSMN1; SMN2 | |
| Octanedioate SCHEMBL30132328 | 0.86 | SMN1; SMN2 (0.59) | ALDH1A1RAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL6319718 | 0.84 | ALDH1A1 (0.66) | ALDH1A1RAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL2170056 | 0.82 | ALDH1A1 (0.64) | ALDH1A1RAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL836745 | 0.82 | SMN1; SMN2 (0.65) | ALDH1A1RAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL28727291 | 0.82 | SMN1; SMN2 (0.65) | ALDH1A1RAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL1827781 | 0.81 | ALDH1A1 (0.53) | ALDH1A1RAB9ANPC1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3610419 | 0.81 | SMN1; SMN2 (0.63) | ALDH1A1RAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL569032 | 0.81 | ALDH1A1 (0.67) | ALDH1A1RAB9ANPC1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618978-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024108147-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2024-05-23 | — | — | WO | claimed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | claimed |
| EP-3472149-B1 | HETEROCYCLIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2023-08-30 | — | — | EP | claimed |
| CN-115594646-A | Novel beta-elemene hydrogen sulfide donor type derivative, preparation method and medical application thereof | 石药集团远大（大连）制药有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-113149979-B | 8- (benzothiazole amide) substituted coumarin compound and preparation method and application thereof | 朗捷睿(苏州)生物科技有限公司 | 2022-11-25 | — | — | CN | claimed |
| EP-3317269-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2022-09-21 | — | — | EP | claimed |
| WO-2022183961-A1 | 8-(BENZOTHIAZOLE AMIDE) SUBSTITUTED COUMARIN COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 朗捷睿(苏州)生物科技有限公司 | 2022-09-09 | — | — | WO | claimed |
| WO-2020020099-A1 | SELENIUM-CONTAINING ISOXAZOLAMINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海星叶医药科技有限公司 | 2020-01-30 | — | — | WO | claimed |
| CN-106414458-B | Novel fused imidazobenzothiazole compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2019-10-29 | — | — | CN | claimed |
| CN-101611015-A | Indazolyl ester and indazolyl amide derivatives for the treatment of glucocorticoid receptor mediated disorders | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | CN | claimed |
| EP-1917246-B1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| EP-1635821-B1 | 4-BROMO-5-(2-CHLORO-BENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID (PHENYL)AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ELAN PHARM INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | claimed |
| WO-2008100622-A2 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | claimed |
| EP-1155017-B1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | SHIRE BIOCHEM INC (CA) | 2003-01-15 | — | — | EP | claimed |
| EP-1034176-A1 | THIOPHENE-SULFONAMIDE COMPOUNDS | PHARMACIA & UPJOHN S.p.A. (IT) | 2000-09-13 | — | — | EP | claimed |
| WO-1999028316-A1 | THIOPHENE-SULFONAMIDE COMPOUNDS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-06-10 | — | — | WO | claimed |
| EP-0341081-B1 | Novel amino acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1995-07-05 | — | — | EP | claimed |
| EP-0341081-A2 | Novel amino acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-11-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207683-A1 | BIARYL-SUBSTITUTED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | ALDH1A1 4560/4885RAB9A 502/4885NPC1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.